DANOFLOXACIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H20FN3O3
Molecular Weight	357.3788
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C[C@@H]2C[C@H]1CN2C3=CC4=C(C=C3F)C(=O)C(=CN4C5CC5)C(O)=O

InChI

InChIKey=QMLVECGLEOSESV-RYUDHWBXSA-N

InChI=1S/C19H20FN3O3/c1-21-7-12-4-11(21)8-22(12)17-6-16-13(5-15(17)20)18(24)14(19(25)26)9-23(16)10-2-3-10/h5-6,9-12H,2-4,7-8H2,1H3,(H,25,26)/t11-,12-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/UCM292024.pdf | https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=95982

Danofloxacin is a quinolone antibacterial agent for veterinary medicine. The drug is approved by FDA for the treatment of bovine infectious respiratory disease under the name Advocin (mesylate salt). Danofloxacin exerts its action by inhibiting bacterial DNA gyrase.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D03646\|https://www.ncbi.nlm.nih.gov/pubmed/8726041\|https://www.ncbi.nlm.nih.gov/pubmed/26078016	Inhibitor 8297
Bacterial DNA gyrase 66 Target ID: CHEMBL2311224 Sources: https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=95982	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bovine infectious respiratory disease 2 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d22c22fc-d530-423c-8d78-ca95fe195ba1&type=display	Curative		Approved 8429	ADVOCIN Approved Use For the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica and Pasteurella multocida and for the control of BRD in beef cattle at high risk of developing BRD associated with Mannheimia haemolytica and Pasteurella multocida. Launch Date 2011

PubMed

Title	Date	PubMed
Pharmacokinetics of danofloxacin after single dose intravenous, intramuscular and subcutaneous administration to loggerhead turtles Caretta caretta.	2008 Dec 22	19244975
Effect of Danofloxacin on Reactive Oxygen Species Production, Lipid Peroxidation and Antioxidant Enzyme Activities in Kidney Tubular Epithelial Cell Line, LLC-PK1.	2013 Dec	23855763
Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.	2017	28052123

Patents

Sample Use Guides

In Vivo Use Guide

Administered by subcutaneous injection at either 8 mg per kilogram of body weight once or 6 mg per kilogram of body weight with treatment repeated once approximately 48 hours following the first injection.

Route of Administration: Other

In Vitro Use Guide

Danofloxacin minimum inhibitory concentration values (MIC90) were 0.06 ug/mL for both Mannheimia haemolytica and Pasteurella multocida.

Name

Type

Language

DANOFLOXACIN

Official Name

English

1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-((1S,4S)-5-METHYL-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)-4-OXO-3-QUINOLINECARBOXYLIC ACID

Systematic Name

English

A180

Brand Name

English

DANOFLOXACIN [GREEN BOOK]

Common Name

English

DANOFLOXACIN [MI]

Common Name

English

3-QUINOLINECARBOXYLIC ACID, 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-7-(5-METHYL-2,5-DIAZABICYCLO(2.2.1)HEPT-2-YL)-4-OXO-, (1S)-

Common Name

English

danofloxacin [INN]

Common Name

English

ADVOCIN

Brand Name

English

Classification Tree Code System Code

CFR

21 CFR 556.169